Identification of definitive serum biomarkers associated with disease activity in primary Sjögren's syndrome

Arthritis Research and Therapy

Volumn 18, Issue 1, 2016, Pages

  Nishikawa, Ayumi ^a   Suzuki, Katsuya ^a   Kassai, Yoshiaki ^b   Gotou, Yuumi ^b   Takiguchi, Maiko ^b   Miyazaki, Takahiro ^b   Yoshimoto, Keiko ^a   Yasuoka, Hidekata ^a   Yamaoka, Kunihiro ^a   Morita, Rimpei ^a   Yoshimura, Akihiko ^a   Takeuchi, Tsutomu ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

Biomarker; Disease activity; Proteomics; Serum protein; Sj gren's syndrome

Indexed keywords

B CELL ACTIVATING FACTOR; BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; CD163 ANTIGEN; CD48 ANTIGEN; CORTICOSTEROID; CXCL13 CHEMOKINE; EPHRIN RECEPTOR B2; PERTECHNETIC ACID TC 99M; PROGRAMMED DEATH 1 LIGAND 2; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; ARTICLE; BLOOD ANALYSIS; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EUROPEAN LEAGUE AGAINST RHEUMATISM SJOGREN SYNDROME DISEASE ACTIVITY INDEX; FEMALE; HIGH THROUGHPUT SCREENING; HUMAN; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE ASSESSMENT; PROTEIN EXPRESSION; PROTEOMICS; SALIVARY GLAND SCINTISCANNING; SJOEGREN SYNDROME; SUBMANDIBULAR GLAND; AGED; BLOOD; MIDDLE AGED; PROCEDURES;

ADULT; AGED; BIOMARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MALE; MIDDLE AGED; PROTEOMICS; SJOGREN'S SYNDROME;

EID: 84969242473     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-016-1006-1     Document Type: Article

References (57)

1. Mariette X, Seror R, Quartuccio L, et al. Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase II study. Ann Rheum Dis. 2015;74:526-31.
2. Brkic Z, Versnel MA. Type I IFN signature in primary Sjögren's syndrome patients. Expert Rev Clin Immunol. 2014;10:457-67.
3. Mavragani CP, Moutsopoulos HM. Sjögren's syndrome. Annu Rev Pathol Mech Dis. 2014;9:273-85.
4. Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, et al. Treatment of primary Sjögren syndrome with rituximab: a randomized trial. Ann Intern Med. 2014;160:233-42.
5. Guellec D, Cornec D, Jousse-Joulin S, et al. Diagnostic value of labial minor salivary gland biopsy for Sjögren's syndrome: a systematic review. Autoimmunity Reviews. 2013;12:416-20.
6. Zhou D, McNamara NA. Macrophages: important players in primary Sjögren's syndrome? Expert Rev Clin Immunol. 2014;10:513-20.
7. Al-Tarawneh SK, Border MB, Dibble CF, et al. Defining salivary biomarkers using mass spectrometry-based proteomics: a systematic review. OMICS. 2011;15:353-61.
8. Deutsch O, Krief G, Konttinen YT, et al. Identification of Sjögren's syndrome oral fluid biomarker candidates following high-abundance protein depletion. Rheumatology (Oxford). 2015;54:884-90.
9. Fleissig Y, Deutsch O, Reichenberg E, et al. Different proteomic protein patterns in saliva of Sjögren's syndrome patients. Oral Dis. 2009;15:61-8.
10. Giusti L, Baldini C, Bazzichi L, et al. Proteomic diagnosis of Sjögren's syndrome. Expert Rev Proteomics. 2007;4:757-67.
11. Hu S, Vissink A, Arellano M, et al. Identification of autoantibody biomarkers for primary Sjögren's syndrome using protein microarrays. Proteomics. 2011;11:1499-507.
12. Peluso G, De Santis M, Inzitari R, et al. Proteomic study of salivary peptides and proteins in patients with Sjögren's syndrome before and after pilocarpine treatment. Arthritis Rheum. 2007;56:2216-22.
13. Ryu OH, Atkinson JC, Hoehn GT, et al. Identification of parotid salivary biomarkers in Sjögren's syndrome by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry and two-dimensional difference gel electrophoresis. Rheumatology. 2006;45:1077-86.
14. Baldini C, Giusti L, Ciregia F, et al. Proteomic analysis of saliva: a unique tool to distinguish primary Sjögren's syndrome from secondary Sjögren's syndrome and other sicca syndromes. Arthritis Res Ther. 2011;13(6):R194.
15. Quartuccio L, Salvin S, Fabris M, et al. BLyS upregulation in Sjögren's syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands. Rheumatology (Oxford). 2013;52:276-81.
16. Gottenberg JE, Seror R, Miceli-Richardo C, et al. Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease acitivity in primary Sjögren's syndrome. data at enrollment in the prospective ASSESS cohort. PLoS One. 2013;8(5):e59868.
17. Maria NI, Brkic Z, Waris M, et al. MxA as a clinically applicable biomarker for identifying systemic interferon type I in primary Sjögren's syndrome. Ann Rheum Dis. 2014;73:1052-9.
18. Seror R, Ravaud P, Bowman S, et al. EULAR Sjögren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren's syndrome. Ann Rheum Dis. 2010;69:1103-9.
19. Moerman RV, Arends S, Meiners PM, et al. EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomized controlled trial. Ann Rheum Dis. 2014;73:472-4.
20. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;6:554-8.
21. Shiboski SC, Shiboski CH, Criswell L, et al. American College of Rheumatology classification criteria for Sjögren's syndrome: a data-driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance cohort. Arthritis Care Res. 2012;64:475-87.
22. Tsuboi H, Hagiwara S, Asashima H, et al. Validation of different sets of criteria for the diagnosis of Sjögren's syndrome in Japanese patients. Mod Rheumatol. 2013;23:219-25.
23. Brito-Zerón P, Kostov B, Solans R, et al. Systemic activity and mortality in primary Sjögren syndrome: predicting survival using the EULAR-SS Disease Activity Index (ESSDAI) in 1045 patients. Ann Rheum Dis. 2014;0:1-8. doi: 10.1136/annrheumdis-2014-206418.
24. Rohloff JC, Gelinas AD, Jarvis TC, et al. Nucleic acid ligands with protein-like side chains: modified aptamers and their use as diagnostic and therapeutic agents. Mol Ther Nucleic Acids. 2014;3:e201.
25. Gold L, Ayers D, Bertino J, et al. Aptamer-based multiplexed proteomic technology for biomarker discovery. PLoS One. 2010;5(12):e15004.
26. TM) platform. Mol Cell Proteomics. 2014;13:1050-64.
27. Yoshimoto K, Tanaka M, Kojima M, et al. Regulatory mechanisms for the production of BAFF and IL-6 are impaired in monocytes of patients of primary Sjögren's syndrome. Arthritis Res Ther. 2011;13(5):R170.
28. Tomlins SA, Mehra R, Rhodes DR, et al. Integrative molecular concept modeling of prostate cancer progression. Nat Genet. 2007;39:41-51.
29. Markeljevic J, Sarac H, Bozina N, et al. Serotonin transporter gene polymorphisms: relation with platelet serotonin level in patients with primary Sjogren's syndrome. J Neuroimmunol. 2015;282:104-9.
30. Sarac H, Markeljevic J, Erdeljic V, et al. Signal hyperintensities on brain magnetic resonance imaging in patients with primary Sjögren's syndrome and frequent episodic tension-type headache; relation to platelet serotonin level and disease activity. J Rheumatol. 2013;40:1360-6.
31. Delaleu N, Mydel P, Kwee I, et al. High fidelity between saliva proteomics and the salivary glands' biological state defines biomarker-signatures for primary Sjögren's syndrome. Arthritis Rheumatol. 2015;67:1084-95.
32. Campar A, Isenberg DA. Primary Sjögren's syndrome activity and damage indices comparison. Eur J Clin Invest. 2010;40:636-44.
33. Nocturne G, Seror R, Fogel O, et al. CXCL13 and CCL11 serum levels and lymphoma and disease activity in primary Sjögren Syndrome. Arthritis Rheumatol. 2015. doi:10. 1002/art.393915.
34. Manzo A, Vitolo B, Humby F, et al. Mature antigen-experienced T helper cells synthesize and secrete the B cell chemoattractant CXCL13 in the inflammatory environment of the rheumatoid joint. Arthritis Rheum. 2008;58:3377-87.
35. Gunn MD, Ngo VN, Ansel KM, et al. A B-cell-homing chemokine made in lymphoid follicles activates Burkitt's lymphoma receptor-1. Nature. 1998;391:799-803.
36. Cyster JG, Ansel KM, Reif K, et al. Follicular stromal cells and lymphocyte homing to follicles. Immunol Rev. 2000;176:181-93.
37. Kramer JM, Klimatcheva E, Rothstein TL, et al. CXCL13 is elevated in Sjögren's syndrome in mice and humans and is implicated in disease pathogenesis. J Leukoc Biol. 2013;94:1079-89.
38. Barone F, Bombardieri M, Manzo A, et al. Association of CXCL13 and CCL21 expression with the progressive organization of lymphoid-like structures in Sjögren's syndrome. Arthritis Rheum. 2005;52:1773-84.
39. Barone F, Bombardieri M, Rosado MM, et al. CXCL13, CCL21, and CXCL12 expression in salivary glands of patients with Sjögren's syndrome and MALT lymphoma: association with reactive and malignant areas of lymphoid organization. J Immunol. 2008;180:5130-40.
40. Fraustman DL, Davis M. TNF receptor 2 and disease: autoimmunity and regenerative medicine. Front Immunol. 2013;4:478.
41. Patel M, Oni L, Midgley A, et al. Increased concentration of plasma TNFR1 and TNFR2 in paediatric lupus nephritis. Lupus. 2016;0:1-5. doi: 10.1177/0961203316631634.
42. Horiuchi T, Mitoma H, Harashima S, et al. Transmembrane TNF-a: structure, function and interaction with anti-TNF agents. Rheumatology. 2010;49:1215-28.
43. Svenungsson E, Gunnarsson I, Fei GZ, et al. Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus. Arthritis Rheum. 2003;48:2533-40.
44. Ferreira GA, Teixeira A, Calderano DC, et al. Atorvastatin reduced soluble receptors of TNF-alpha in systemic lupus erythematosus. Clin Exp Rheumatol. 2016;34:42-8.
45. Turan B, Pfister K, Diener PA, et al. Soluble tumour necrosis factor receptors sTNFR1 and sTNFR2 are produced at sites of inflammation and are markers of arthritis activity in Behçet's disease. Scand J Rheumatol. 2008;37:135-41.
46. Koski H, Janin A, Humphreys-Beher MG, et al. Tumor necrosis factor-alpha and receptor for it in labial salivary glands in Sjögren's syndrome. Clin Exp Rheumatol. 2001;19:131-7.
47. Elishmereni M, Levi-Schaffer F. CD48: a co-stimulatory receptor of immunity. Int J Biochem Cell Biol. 2011;43:25-8.
48. Gangwar RA et al. sCD48 is anti-inflammatory in S. aureus Enterotoxin B induced eosinophilic inflammation. Allergy. 2016. doi: 10.1111/all.12851.
49. Ariel M et al. CD48 is an allergen and IL-3-induced activation molecule on eosinophils. J Immunol. 2006;177:77-83.
50. Smith GM et al. Detection of a soluble form of the leukocyte surface antigen CD48 in plasma and its elevation in patients with lymphoid leukemias and arthritis. J Clinical Immunol. 1997;17:502-9.
51. Boles KS et al. 2B4 (CD244) and CS1: novel members of the CD2 subset of the immunoglobulin superfamily molecules expressed on natural killer cells and other leukocytes. Immunol Rev. 2001;181:234-49.
52. Candon S, Gottenberg JE, Bengoufa D, et al. Quantitative assessment of antibodies to ribonucleoproteins in primary Sjögren's syndrome: correlation with B-cell biomarkers and disease activity. Ann Rheum Dis. 2009;68:1208-12.
53. Mariette X, Roux S, Zhang J, et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome. Ann Rheum Dis. 2003;62:168-71.
54. Zhang J, Roschke V, Baker KP, et al. Cutting edge: a role for B lymphocytestimulator in systemic lupus erythematosus. J Immunol. 2001;166:6-10.
55. Cheema GS, Roschke V, Hilbert DM, et al. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum. 2001;44:1313-9.
56. Dai S, Jia R, Zhang X, et al. The PD-1/PD-Ls pathway and autoimmune diseases. Cell Immunol. 2014;290:72-9.
57. Messal N, Serriari NE, Pastor S, et al. PD-L2 is expressed on activated human T cells and regulates their function. Mol Immunol. 2011;48:2214-9.